mbx 1416
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 18, 2023 (NCT06036784)
Timeline
Indications
Mechanism of action
- Glucagon-like peptide 1 receptorANTAGONIST
GLP1R antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07029412 | Phase 2 | Aug 26, 2025 | MBX Biosciences |
| NCT06036784 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2023 | MBX Biosciences, ProSciento, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MBX Biosciences | For profit | 2 | 2 | 1 | 2023 |
| ProSciento, Inc. | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1